Targeting ASIC1 in primary progressive multiple sclerosis: Evidence of neuroprotection with amiloride

Brain

Volumn 136, Issue 1, 2013, Pages 106-115

  Arun, Tarunya ^a,b   Tomassini, Valentina ^a,b,c   Sbardella, Emilia ^a,b,d   De Ruiter, Michiel B ^b,e   Matthews, Lucy ^a,b   Leite, Maria Isabel ^a   Gelineau Morel, Rose ^f   Cavey, Ana ^a   Vergo, Sandra ^a,g   Craner, Matt ^a,g   Fugger, Lars ^a,g   Rovira, Alex ^h   Jenkinson, Mark ^b   Palace, Jacqueline ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f Houston   (United States)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

acid sensing ion channel; amiloride; MRI; multiple sclerosis; neuroprotection

Indexed keywords

ACID SENSING ION CHANNEL; AMILORIDE; CALCIUM; SODIUM;

ADULT; AGED; ARTICLE; AUTOPSY; BRAIN SIZE; BRAIN TISSUE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORPUS CALLOSUM; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; DRUG EFFECT; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GRAY MATTER; HUMAN; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVE FIBER; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PYRAMIDAL TRACT; TISSUE INJURY; TRANSLATIONAL RESEARCH; WHITE MATTER;

EID: 84873333551     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aws325     Document Type: Article

References (38)

1. Alexander AL, Lee JE, Lazar M, Field AS. Diffusion tensor imaging of the brain. Neurotherapeutics 2007; 4: 316-29.
2. Barkhof F, Calabresi PA, Miller DH, Reingold SC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009; 5: 256-66.
3. Bechtold DA, Kapoor R, Smith KJ. Axonal protection mediated by flecainide therapy in experimental inflammatory demyelinating disease. J Neurol 2002; 249: 204.
4. Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000; 48: 893-901.
5. Bodini B, Battaglini M, De Stefano N, Khaleeli Z, Barkhof F, Chard D, et al. T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2011; 82: 72-7.
6. Bodini B, Cercignani M, Khaleeli Z, Miller DH, Ron M, Penny S, et al. Corpus callosum damage predicts disability progression and cognitive dysfunction in primary-progressive MS after five years. Hum Brain Mapp 2012; doi:10.1002/hbm.21499. [Epub ahead of print Feb 132012].
7. Cifelli A, Arridge M, Jezzard P, Esiri MM, Palace J, Matthews PM. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002; 52: 650-3.
8. De Stefano N, Giorgio A, Battaglini M, Rovaris M, Sormani MP, Barkhof F, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010; 74: 1868-76.
9. De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley J, Francis GS, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998; 121 (Pt 8): 1469-77.
10. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-9.
11. Fern R, Ransom BR, Stys PK, Waxman SG. Pharmacological protection of CNS white matter during anoxia: actions of phenytoin, carbamazepine and diazepam. J Pharmacol Exp Ther 1993; 266: 1549-55.
12. Friese MA, Craner MJ, Etzensperger R, Vergo S, Wemmie JA, Welsh MJ, et al. Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat Med 2007; 13: 1483-9.
13. Frost C, Kenward MG, Fox NC. Optimizing the design of clinical trials where the outcome is a rate. Can estimating a baseline rate in a run-in period increase efficiency? Stat Med 2008; 27: 3717-31.
14. Gasperini C, Rovaris M, Sormani MP, Bastianello S, Pozzilli C, Comi G, et al. Intra-observer, inter-observer and inter-scanner variations in brain MRI volume measurements in multiple sclerosis. Mult Scler 2001; 7: 27-31.
15. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460-71.
16. Houtchens MK, Benedict RH, Killiany R, Sharma J, Jaisani Z, Singh B, et al. Thalamic atrophy and cognition in multiple sclerosis. Neurology 2007; 69: 1213-23.
17. Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 2010; 9: 681-8.
18. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006; 129 (Pt 3): 584-94.
19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
20. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128 (Pt 11): 2705-12.
21. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003; 60: 44-51.
22. Lo AC, Black JA, Waxman SG. Neuroprotection of axons with phenytoin in experimental allergic encephalomyelitis. Neuroreport 2002; 13: 1909-12.
23. Montalban X, Sastre-Garriga J, Tintore M, Brieva L, Aymerich FX, Rio J, et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler 2009; 15: 1195-205.
24. Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp 2002; 15: 1-25.
25. Nikolaeva MA, Mukherjee B, Stys PK. Na+-dependent sources of intra-axonal Ca2 + release in rat optic nerve during in vitro chemical ischemia. J Neurosci 2005; 25: 9960-7.
26. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840-6.
27. Reich DS, Zackowski KM, Gordon-Lipkin EM, Smith SA, Chodkowski BA, Cutter GR, et al. Corticospinal tract abnormalities are associated with weakness in multiple sclerosis. AJNR 2008; 29: 333-9.
28. Rocca MA, Mesaros S, Pagani E, Sormani MP, Comi G, Filippi M. Thalamic damage and long-term progression of disability in multiple sclerosis. Radiology 2010; 257: 463-9.
29. Rocca MA, Mezzapesa DM, Falini A, Ghezzi A, Martinelli V, Scotti G, et al. Evidence for axonal pathology and adaptive cortical reorganization in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis. NeuroImage 2003; 18: 847-55.
30. Schott JM, Frost C, Whitwell JL, Macmanus DG, Boyes RG, Rossor MN, et al. Combining short interval MRI in Alzheimer's disease: implications for therapeutic trials. J Neurol 2006; 253: 1147-53.
31. Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE, Mackay CE, et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. NeuroImage 2006; 31: 1487-505.
32. Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. NeuroImage 2002; 17: 479-89.
33. Stys PK, Lopachin RM. Mechanisms of calcium and sodium fluxes in anoxic myelinated central nervous system axons. Neuroscience 1998; 82: 21-32.
34. Vergo S, Craner MJ, Etzensperger R, Attfield K, Friese MA, Newcombe J, et al. Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model. Brain 2011; 134 (Pt 2): 571-84.
35. Waxman SG. Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status. Nat Clin Pract Neurol 2008; 4: 159-69.
36. Wemmie JA, Askwith CC, Lamani E, Cassell MD, Freeman JH Jr, Welsh MJ. Acid-sensing ion channel 1 is localized in brain regions with high synaptic density and contributes to fear conditioning. J Neurosci 2003; 23: 5496-502.
37. Wolinsky JS, Narayana PA, O'Connor P, Coyle PK, Ford C, Johnson K, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007; 61: 14-24.
38. Tallantyre EC, Bo L, Al-Rawashdeh O, Owens T, Polman CH, Lowe JS, et al. Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Mult Scler 2010; 16: 406-11.